Shots:

• The P-II OPTIC study involves assessing three initial doses of Iclusig (15/30/45 mg) in 283 patients with CML in CF- or who had documented history of the presence of the T315I mutation after receiving any number of previous TKIs
• With an average follow-up of~ 21 mos.- the interim analysis showed that maximum BCR- ABL1 ≤1% in 12mos.achieved in 45mg/ day (38.7%)- and responses were maintained with 15 mg / day- 75% patients with 45mg & 88% with 30mg were able to maintain BCR- ABL1 ≤1% for up to 2yrs.
• Iclusig is a kinase inhibitor directed mainly to the protein BCR-ABL1- thus inhibits the activity of BCR-ABL1 and its mutations. The company will utilize these data to file sNDA to the US FDA for the therapy

Click here ­to­ read full press release/ article 

 Ref: Takeda | Image: Takeda